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Summary
In 1997, the Swiss Blood Stem Cell Transplantation Group
(SBST) initiated a mandatory national registry for all
haematopoietic stem cell transplants (HCTs) in Switzer-
land. As of 2016, after 20 years, information was available
for 7899 patients who had received an HCT (2781 allo-
geneic [35%] and 5118 autologous [65%]). As some pa-
tients had more than one transplant the total number of
transplants was 3067 allogeneic and 6448 autologous. We
compared patient characteristics and outcome of the first
decade (1997–2006) and second decade (2007-2016) of
the registry. There were numerous changes over time.
For allogeneic HCT, transplant rates, and therefore use
of HCT technology, increased from 14 to 21.8 HCTs per
1 million inhabitants per year from the first to the second
decade. Likewise autologous HCTs increased from 24.8 to
37.2 annually corrected for population growth. Allogene-
ic transplant recipients were older (38.4 vs 48.3 years)
and more frequently had unrelated donors in the second
decade. Similarly, age increased for recipients of autolo-
gous HCT (50.8 vs 56.4 years).
Analysis of outcome showed that the probabilities of over-
all and progression-free survival were stable over time, in
spite of the treatment of older and higher risk patients.
In multivariate analysis, nonrelapse mortality decreased in
recipients of allogeneic HCT (relative risk 0.68, 95% confi-
dence interval 0.52–0.87) over the two decades. Improve-
ment in adjusted nonrelapse mortality compensated for
the fact that higher risk patients were treated in more re-
cent years, resulting in similar overall survival. Five-year
survival probabilities were 56% (53–59%) in the first and
54% (51–57%) in the second decade for allogeneic HCT,
and 59% (57–61%) in the first and 61% (59–63%) in the
second decade for autologous HCT. Detailed analyses of
changes over time are presented. This study included all
HCTs performed in Switzerland during the period of ob-
servation and the data are useful for quality assurance
programmes, healthcare cost estimation and healthcare
planning. Between 50 and 60% of patients were long-term
survivors after both types of HCT, indicating growing pop-
ulations of surviving patients requiring long-term care and
observation.
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Introduction
Transplantation of haematopoietic stem cells (HCT) is to-
day an established therapy and has expanded rapidly over
recent decades. It is used for many severe acquired or
congenital disorders of the haematopoietic system and for
chemo, radio or immunosensitive malignancies. Stem cells
from bone marrow, peripheral blood or cord blood are
used, and may be derived from the patients themselves for
autologous HCT or from siblings, other family members or
unrelated donors for allogeneic HCT [1–6]. The goals of
HCT are manifold. HCT can restore bone marrow function
in patients with congenital deficiencies or acquired mal-
function. Autologous transplants can be used to shorten the
period of severe pancytopenia in the context of high-dose
chemo-/radiotherapy. Allogeneic HCT provides a power-
ful targeted antitumour effect in the form of a graft-ver-
sus-host or graft-versus-tumour reaction in the treatment of
haematological or nonhaematological malignancies. HCT
can induce tolerance to donor tissue in solid organ trans-
plantation and, last but not least, HCT can reset the ontoge-
ny of the immune system in the treatment of autoimmune
diseases [7]. HCT has a long history in Switzerland [8, 9].
HCT is a complex and cost-intensive therapeutic proce-
dure. In Switzerland, costs of the procedure are covered
by health insurance, based on the guidance of the Federal
Office for Social Insurance. In this guidance diseases are
listed as “established”, “in evaluation with full payment”,
“in evaluation without payment” or “not established”. On
the occasion of a prior revision (2002), the Federal Office
requested an analysis of this therapeutic instrument and
asked for an evaluation registry. In anticipation of this re-
quirement, in 1997 the Swiss Blood Stem Cell Transplan-
tation Group (SBST) established a central registry for all
HCTs in Switzerland. As reporting is mandatory, this re-
port includes all patients receiving an autologous or al-
logeneic HCT in Switzerland over the past 20 years
(1997–2016) and describes changes in patient characteris-
tics and treatment outcomes over time.
Patients and methods
Data collection
In accordance with and in preparation for the Swiss trans-
plant law, from 1997 data relating to all HCTs performed
in Switzerland were collected. Data collection is based on
the Minimal Essential Data sets (Med-A) of the European
Society for Blood and Marrow Transplantation (EBMT).
Patient data are updated annually. All patients receiving a
transplant between 1 January 1997 and 31 December 2016
were included in this analysis. The data cut-off date was
31 July 2017, giving a minimum follow up of 6 months for
all patients. Median follow-up for all allograft recipients
was 4.4 years (quartiles 1.6–9.2) and for autografts was 3.7
years (1.1–7.4).
Definitions for haematopoietic stem cell transplanta-
tion
HCT was defined according to the criteria of the EBMT
[10]. An HCT is the infusion of haematopoietic stem cells
given with the intention to replace the pretransplant
haematopoietic system of the recipient. Patient-related out-
comes are reported. Some patients received more than one
transplant and these are described for characteristics where
the focus is on procedures.
A retransplant was defined as HCT given after a previous
(either autologous or allogeneic) HCT, for the treatment
of relapse or rejection. Multiple transplants are defined
as subsequent infusions of stem cells in the context of
planned double or triple transplant protocols.
Participating teams
HCT was performed during the defined observation period
in Aarau (Kantonsspital), Basel (University Hospitals),
Bellinzona (Kantonsspital), Berne (University Hospital),
Geneva (University Hospital), Lausanne (University Hos-
pital), St. Gallen (Kantonsspital) and Zurich (University
Hospital, University Children’s Hospital and the Hirslan-
den Clinic). Allogeneic HCTs were restricted to Basel,
Geneva, Zurich University Hospital and Zurich University
Children’s Hospital; autologous transplants were per-
formed at all centres. Since 1997, autologous HCTs in the
French-speaking part of Switzerland were performed pri-
marily in Lausanne, allogeneic HCTs primarily in Geneva.
Paediatric transplants were performed in Basel (allogeneic
and autologous), Berne (autologous), Geneva (allogeneic
and autologous), Lausanne (autologous) and Zurich (allo-
geneic and autologous).
All teams were required to have ethics committee approval
of data collection, and all patients or their legal representa-
tives gave written informed consent before the transplant.
Statistical analysis
Descriptive statistics included median and range for con-
tinuous variables and frequencies for categorical variables.
As the observation period covered 20 years, we used the
first and second decade of the registry to compare changes
in the use of technology, indications and outcomes over
time. Comparison among groups was by use of the
Kruskal-Wallis test for continuous variables and the chi-
squared test for categorical variables. Transplant rates were
calculated as number of allogeneic and autologous HCTs
corrected per 1 million inhabitants per year for each of the
decades, accounting for population growth in Switzerland.
Outcomes measured were overall survival and progres-
sion-free survival, determined as the Kaplan-Meier esti-
mates, and nonrelapse mortality and relapse incidence de-
termined from cumulative incidence curves adjusted for
competing risks as appropriate. For overall survival, death
was the event, for progression-free survival it was time
to relapse of the original disease or death measured from
the time of transplant. Nonrelapse mortality was defined
as death without relapse. Groups were compared using the
log-rank test for the Kaplan-Meier estimates and Fine and
Gray for cumulative incidence. A p-value of ≤0.05 was
considered to be statistically significant.
Multivariate models were constructed using the Cox re-
gression model or the competing risk model as appropriate
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Table 1: a: Demographic characteristics and transplant technology for allogeneic haematopoietic cell transplants by decade for the years 1997–2016.
1997–2006 2007–2016 Total p-value
n % n % n %
Patients (first allograft)
No. 1st. allograft 997 88.8 1784 91.8 2781 90.7
No. not 1st allograft 126 11.2 160 8.2 286 9.3
Centre 0.01
1 427 42.8 654 36.7 1081 38.9
2 233 23.4 456 25.6 689 24.8
3 236 23.7 488 27.4 724 26
4 101 10.1 186 10.4 287 10.3
Disease <0.0001
Acute myeloid leukaemia 314 31.5 651 36.5 965 34.7
Acute lymphoid leukaemia 163 16.3 272 15.2 435 15.6
Chronic lymphocytic leukaemia 23 2.3 54 3 77 2.8
Chronic myeloid leukaemia 152 15.2 59 3.3 211 7.6
Combined myelodysplastic/myeloproliferative 85 8.5 215 12.1 300 10.8
Myeloproliferative neoplasms 22 2.2 93 5.2 115 4.1
Hodgkin’s lymphoma 21 2.1 35 2 56 2
Non-Hodgkin’s lymphoma 57 5.7 122 6.8 179 6.4
Plasma cell disorder 54 5.4 113 6.3 167 6
Solid tumours 8 0.8 2 0.1 10 0.4
Bone marrow failure 51 5.1 59 3.3 110 4
Inherited disorders of metabolism 6 0.6 17 1 23 0.8
Primary immune disorders 29 2.9 57 3.2 86 3.1
Haemoglobinopathy 9 0.9 18 1 27 1
Histiocytic disorders 3 0.3 14 0.8 17 0.6
Others 0 0 3 0.2 3 0.1
Disease stage at transplant <0.0001
Early 526 52.8 919 51.5 1445 52
Intermediate 229 23 530 29.7 759 27.3
Late 242 24.3 335 18.8 577 20.7
Gender 0.30
Male 584 58.6 1081 60.6 1665 59.9
Female 413 41.4 703 39.4 1116 40.1
Age group <0.0001
0–20 years 229 23 289 16.2 518 18.6
20–40 years 300 30.1 344 19.3 644 23.2
40–60 years 413 41.1 786 44.1 1199 43.1
60–70 years 55 5.5 343 19.2 398 14.3
>70 years 0 0 22 1.2 22 0.8
Median age (years) 38.4 48.3 44.3
Age range (years 0.15–68.7 0.24–74.2 0.15–74.2
Donor <0.0001
HLA identical sibling 586 58.8 653 36.6 1239 44.6
Twin 17 1.7 9 0.5 26 0.9
Other relative 93 9.3 120 6.7 213 7.7
Unrelated 301 30.2 1002 56.2 1303 46.9
Stem cell source <0.0001
Bone marrow 304 30.5 302 16.9 606 21.8
Peripheral blood 679 68.1 1417 79.4 2096 75.4
Cord blood 14 1.4 65 3.6 79 2.8
Risk score <0.0001
0–1 158 15.8 166 9.3 324 11.7
2–3 471 47.2 810 45.4 1281 46.1
4–5 326 32.7 676 37.9 1002 36
6–7 42 4.2 132 7.4 174 6.3
Comorbidities
Yes Data not collect-
ed
– 631 35.4 631 35.4
No – 601 33.7 601 33.7
Missing – 552 30.9 552 30.9
Cytomegalovirus status (donor-recipient) 0.16
Neg-neg 201 34.4 555 32.4 756 32.9
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1997–2006 2007–2016 Total p-value
n % n % n %
Pos-neg 87 14.9 215 12.5 302 13.1
Pos-pos 195 33.4 588 34.3 783 34.1
Neg-pos 101 17.3 357 20.8 458 19.9
Sex match (donor-recipient) 0.74
Male-male 366 36.9 684 38.4 1050 37.8
Female-male 217 21.9 396 64.6 613 22.1
Male-female 212 21.3 352 19.7 564 20.3
Female-female 198 19.9 351 19.7 549 19.8
Conditioning <0.0001
Non-myeloablative 214 26.1 704 39.6 918 35.3
Myeloablative 607 73.9 1075 60.4 1682 64.7
Total body irradiation <0.0001
No 382 39.1 1151 64.7 1533 55.6
Yes 595 60.9 629 35.3 1224 44.4
T-cell depletion (in vivo or in vitro) <0.0001
No 683 68.5 651 36.5 1334 48
Yes 314 31.5 1133 63.5 1447 52
[11]. All variables detailed in tables 1 and 2 (see “Results”)
were included in the model and removed by backward se-
lection. Only variables with p ≤0.05 were retained. Decade
was the variable of interest and therefore forced into each
of the models. A Cox regression model was used for over-
all and progression-free survival, whereas the model of
Fine and Gray was used, because of competing risks, for
nonrelapse mortality and relapse. Models of allogeneic
HCT were stratified by centre because of a significant cen-
tre effect (not the objective of this analysis). Comorbid
conditions were those conditions that are likely to affect
the outcome of the transplant but may not be directly re-
lated to the indication for transplant. This information was
not available for the majority of patients and is therefore
not included in the models. None of the variables tested vi-
olated the proportionality assumption, and there were no
first-order interactions.
Results
Numbers of HCTs
There were in total 9515 transplants over the 20-year pe-
riod, 3067 (32%) allogeneic and 6448 (68%) autologous.
As some patients received more than one transplant, the to-
tal numbers of allogeneic and autologous HCT recipients
were 2781 and 5118, respectively. Of the allogeneic HCTs,
286 were repeated transplants, mostly due to relapse. Of
the autologous HCTs, 1330 were repeated transplants, ei-
ther due to relapse or as part of a planned sequential trans-
plant protocol. Of the 3067 allogeneic HCTs, 1123 (37%)
were performed in the first decade (1997–2006) and 1944
(63%) in the second decade (2007–2016). Corresponding
numbers of autologous HCTs were 2689 (42%) in the first
decade and 3759 (58%) in the second decade, showing an
increase in transplant activity by 73% for allogeneic HCT
and 40% for autologous HCT. Transplant rates, and there-
fore use of HCT technology, increased in allogeneic HCT
from 14 to 21.8 HCTs per 1 million inhabitants per year
from the first to the second decade. Likewise, autologous
HCT increased from 24.8 to 37.2, annually corrected for
population growth.
Indications and demographic data
Table 1 shows demographic characteristics and transplant
technology separately for allogeneic (Table 1a) and autol-
ogous (Table 1b) HCT.
Table 1a shows that the number of patients receiving an
allogeneic HCT increased from 997 to 1784 when com-
paring the first (1997–2006) and second (2007–2016)
decades. The main indications for allogeneic HCT were
acute and chronic leukaemia, with the most notable change
in chronic myeloid leukaemia, which decreased from 15.2
to 3.3% during the period of observation owing to the de-
velopment of potent kinase inhibitor drugs. Most other in-
dications showed a proportional increase. The median age
increased from 38 to 48 years from 1997 to 2016 and
the proportion of unrelated donors increased dramatically.
There were changes in the stem cell source (less bone mar-
row) and use of T-cell depletion (massive increase of in
vitro or in vivo T-cell depletion strategies) and, more re-
cently, patients had higher EBMT risk scores (the EBMT
risk score includes variables associated with mortality after
HCT and is referenced in [4] and [15].
Table 1b shows autologous HCT over the two decades;
the number of patients receiving an autologous HCT in-
creased from 2042 to 3076. Indications were mainly lym-
phoid neoplasia, with the most impressive increases in
plasma cell disorders (704 to 1486) and non-Hodgkin’s
lymphoma (577 to 963). Median age increased from 50.8
to 56.4 years. For autologous HCT, the stem cell source
was almost exclusively peripheral blood.
Outcomes
Univariate analyses of overall and progression-free sur-
vival in the first and second decade are shown in table 2a
and figure 1 for allogeneic HCT (without significant dif-
ference between decades) and for autologous HCT in table
2b and figure 2. Figure 1 also shows nonrelapse mortality
and relapse incidence per decade; nonrelapse mortality was
lower in more recent years, but the unadjusted difference
is minor (p = 0.08 in univariate and p = 0.002 in multivari-
ate analysis). Figures 1 and 2 (and tables 2a and 2b) show
that OS at 5 years after allogeneic and autologous HCT
is around 55 and 60%, respectively, for all patients trans-
planted in Switzerland. Figure 3 shows overall survival by
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EBMT risk score; the score was not used for multivariate
analysis as all the elements contributing to the score were
analysed as separate variables. It is nevertheless of interest
to see how risk score affected survival with little change
between the decades. Univariate outcomes for autologous
HCT are shown in table 2b.
Results of multivariate analyses are shown in table 3a for
allogeneic and table 3b for autologous HCT. Significant
factors impacting on outcome in allogeneic HCT were
disease type, disease stage, patient age and donor type
for all outcomes, and the use of T-cell depletion, condi-
tioning intensity, stem cell source and donor-recipient cy-
tomegalovirus status for some of the outcomes. The decade
of transplantation was significant only in models of nonre-
lapse mortality where the risks of death not associated with
relapse was 0.68 (95% confidence interval 0.52–0.87,) in
Table 1b: Demographic characteristics and transplant technology for autologous haematopoietic cell transplants by decade for the years 1997–2016.
1997-2006 2007-2016 Total p-value
n % n % n %
Patients (first autograft)
No. 1st autograft 2042 75.9 3076 81.8 5118 79.4
No. not 1st autograft 647 24.1 683 18.2 1330 20.6
Centre <0.0001
1 170 8.3 251 8.2 421 8.2
2 217 10.6 306 9.98 523 10.2
3 124 6.1 142 4.6 266 5.2
4 347 17 861 28 1208 23.6
5 18 0.9 1 0 19 0.4
6 575 28.2 592 19.2 1167 22.8
7 135 6.6 206 6.7 341 6.7
8 418 20.5 651 21.2 1069 20.9
9 38 1.9 36 1.2 74 1.4
10 0 0 30 1 30 0.6
Disease <0.0001
Acute myeloid leukaemia 145 7.1 182 5.9 327 6.4
Acute lymphoid leukaemia 55 2.7 18 0.6 73 1.4
Chronic lymphocytic leukaemia 18 0.9 4 0.1 22 0.4
Chronic myeloid leukaemia 12 0.6 0 0 12 0.2
Combined myelodysplastic/myeloproliferative 15 0.7 5 0.2 20 0.4
Hodgkin’s lymphoma 179 8.8 166 5.4 345 6.7
Non-Hodgkin’s lymphoma 577 28.3 963 31.3 1540 30.1
Plasma cell disorder 704 34.5 1486 48.3 2190 42.8
Solid tumours 328 16.1 237 7.7 565 11
Autoimmune disorders 9 0.4 15 0.5 24 0.4
Disease stage at transplant <0.0001
Early 862 42.2 1433 46.6 2295 44.8
Intermediate 448 21.9 1137 37 1585 31
Late 732 35.8 506 16.4 1238 24.2
Gender 0.25
Male 1254 61.4 1938 63 3192 62.4
Female 788 38.6 1138 37 1926 37.9
Age group <0.0001
0–20 years 147 7.2 154 5 301 5.9
20–40 years 427 20.9 356 11.6 783 15.3
40–60 years 1083 53 1425 46.3 2508 49
60–70 years 371 18.2 1052 34.2 1423 27.8
>70 years 14 0.7 89 2.9 103 2
Median age (years) 50.8 56.4 54.3
Age range (years 0.65–76.5 0.64–77.5 0.64–77.5
Stem cell source 0.02
Bone marrow 14 0.7 8 0.3 22 0.4
Peripheral blood 2028 99.3 3068 99.7 5096 99.6
Cord blood 0 0 0 0 0 0
Risk score <0.0001
0–1 99 4.8 119 3.9 218 4.3
2–3 1249 61.2 2295 74.6 3544 69.2
4–5 694 34 662 21.5 1356 26.5
Comorbidities
Yes Data not collected – 209 6.8 209 6.8
No – 361 11.7 361 11.7
Missing – 2506 81.5 2506 81.5
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Table 2: a: Univariate analysis of overall and progression-free survival for allogeneic haematopoietic cell transplants by decade for the years 1997–2016.
1997–2006 2007–2016
Overall survival
at 5 years
p-value Progression-free
survival at 5
years
p-value Overall survival at
5 years
p-value Progression-
free survival at 5
years
p-value
Patients receiving first allograft (n) 997 997 1784 1784
56% (53–59%) 47% (44–50%) 54% (51–57%) 46% (43–49%)
Disease <0.0001 <0.0001 <0.0001 <0.0001
Acute myeloid leukaemia 48% (42–54%) 46% (40–52%) 47% (42–52%) 45% (44–58%)
Acute lymphoid leukaemia 47% (39–55%) 42% (34–50%) 64% (57–71%) 51% (34–50%)
Chronic lymphocytic leukaemia 65% (45–85%) 57% (37–77%) 56% (40–72%) 42% (28–56%)
Chronic myeloid leukaemia 76% (69–83%) 55% (47–63%) 61% (46–76%) 51% (35–67%)
Combined myelodysplastic/myeloprolif-
erative
41% (30–52%) 35% (25–45%) 50% (42–58%) 41% (33–49%)
Myeloproliferative neoplasms 59% (38–80%) 46% (25–67%) 61% (48–74%) 49% (36–62%)
Hodgkin’s lymphoma 55% (33–77%) 21% (2–40%) 42% (22–62%) 33% (14–52%)
Non-Hodgkin’s lymphoma 63% (50–76%) 49% (36–62%) 56% (46–66%) 46% (35–57%)
Plasma cell disorder 48% (34–62%) 28% 16–40%) 34% (24–44%) 19% (11–27%)
Solid tumours 0% 0% 50% (0–100%) 0%
Bone marrow failure 77% (65–89%) 77% (65–89%) 68% (54–82%) 69% (55–83%)
Inherited disorders of metabolism 100% 50% (10–90%) 83% (63–100%) 75% (50–100%)
Primary immune disorders 79% (64–94%) 70% (57–87%) 83% (70–96%) 71% (55–87%)
Haemoglobinopathy 89% (69–100%) 89% (69–100%) 100% 94% (82–100%)
Histiocytic disorders 67% (13–100%) 67% (13–100%) 91% (74–100%) 91% (74–100%)
Others – – 100% 100%
Disease stage at transplant <0.0001 <0.0001 <0.0001 <0.0001
Early 70% (66–74%) 60% (56–64%) 65% (61–69%) 57% (53–61%)
Intermediate 50% (43–57%) 41% (34–48%) 50% (45–55%) 41% (36–46%)
Late 31% (25–37%) 23% (18–28%) 31% (25–37%) 24% (19–29%)
Age group <0.0001 <0.0001 <0.0001 <0.0001
0–20 years 63% (57–69%) 57% (50–64%) 73% (67–79%) 67% (60–74%)
20–40 years 61% (55–67%) 51% (45–57%) 55% (49–61%) 45% (39–51%)
40–60 years 52% (47–57%) 40% (35–45%) 51% (47–55%) 42% (38–46%)
60–70 years 30% (18–42%) 27% (15–39%) 45% (38–42%) 40% (34–46%)
>70 years – – 26% (0–55%) 15% (0–41%)
Donor <0.0001 <0.0001 <0.0001 0.001
HLA identical sibling 63% (59–67%) 52% (48–56%) 61% (57–65%) 51% (46–56%)
Twin 59% (35–83%) 29% (7–51%) 76% (46–100%) 64% (29–98%)
Other relative / haploidentical 44% (34–54%) 33% (23–43%) 35% (22–48%) 33% (20–46%)
Unrelated 45% (39–51%) 41% (35–47%) 50% (46–54%) 43% (39–47%)
Stem cell source 0.03 <0.0001 0.02 0.001
Bone marrow 63% (57–69%) 58% (52–64%) 66% (59–73%) 56% (49–63%)
Peripheral blood 52% (48–56%) 41% (37–45%) 51% (48–55%) 44% (41–47%)
Cord blood 57% 31–83%) 57% (31–83%) 56% (43–69%) 46% (33–59%)
Risk score <0.0001 <0.0001 <0.0001 <0.0001
0–1 78% (71–85%) 68% (61–75%) 83% (76–90%) 72% (64–80%)
2–3 63% (59–67%) 54% (49–59%) 60% (56–64%) 52% (48–56%)
4–5 39% (34–44%) 28% (23–33%) 45% (40–50%) 37% (33–41%)
6–7 26% (12–40%) 24% (11–35%) 30% (20–40%) 25% (16–34%)
Conditioning 0.002 <0.0001 0.03 0.03
Non-myeloablative 48% (41–55%) 36% (29–43%) 48% (43–53%) 42% (37–47%)
Myeloablative 59% (55–63%) 50% (46–55%) 57% (53–61%) 48% (44–52%)
T-cell depletion (in vivo or in vitro) 0.32 0.01 0.01 <0.0001
No 57% (53–61%) 51% (47–55%) 50% (45–55%) 40% (36–44%)
Yes 53% (47–59%) 38% (33–43%) 57% (53–61%) 50% (46–54%)
the later decade as compared with the earlier decade. In
table 3b, models of autologous HCT are shown; for none
of the outcomes analysed was the decade of transplantation
significantly associated with outcome.
Discussion
This report illustrates experience with haematopoietic cell
transplantation in Switzerland over the 20 year period from
1997 to 2016 and it describes the current status. The report
provides data on transplant activity and characteristics of
treated patients, and technology used, and gives valuable
information on outcome. Transplant activity generally in-
creased over the observation period with an increase of
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73% from the first to the second decade in allogeneic HCTs
and 40% in autologous HCTs. This reflects trends seen in
Europe, where corresponding increases were 52 and 47%.
The increase in transplant activity in Switzerland was with-
in the range of neighbouring European nations [12].
In the comparison of the two decades, some trends become
evident. Patients receiving allogeneic HCT in the later
decade were older, had higher risk scores, more often re-
ceived stem cells from unrelated donors and, because of
their higher risk status, probably also had more commonly
received reduced intensity conditioning regimens and
some form of T-cell depletion [13]. Outcome data were rel-
atively stable, showing similar survival probabilities in the
later decade but lower nonrelapse mortality. This lack of
progress could be seen as a disappointment, but given that
treated cohorts differed and that the later cohort includ-
ed more high-risk patients, the outcome results appear en-
couraging and probably reflect therapeutic progress. Ad-
justed treatment-associated mortality risks were decreased
by 32% in the later decade. The resulting message, there-
fore, is that currently older patients can be treated with
use of more complex transplant technology and with re-
sults similar to those of younger patients treated in previ-
ous years; in multivariate analysis mortality related to the
procedure was clearly less.
For autologous transplantation, effects were similar but
less marked. The most important increase was in autolo-
gous HCT for myeloma, which doubled over the decades.
This was related to confirmation of the use of high-dose
chemotherapy as a first-line treatment in myeloma [14],
even now, in the era of modern drug treatment. As with al-
logeneic HCT, the age of treated patients increased by ap-
proximately 6 years. In spite of the treatment of older pa-
tients, outcome was not worse in later cohorts. Nonrelapse
mortality with autologous HCT is consistently low, with
little room for improvement (see fig. 2c).
Autologous and allogeneic HCT have different patterns of
outcome. Nonrelapse mortality was lower with autologous
HCT than with allogeneic HCT; on the other hand, the re-
lapse rate was higher with autologous HCT and survival
curves indicated an ongoing risk of relapse over time. Out-
come of HCT is better when transplants are performed at
an early stage of the disease. Nonrelapse mortality and risk
of relapse increases in patients receiving transplants when
their disease is at an advanced stage.
Total transplant rates, (the numbers of transplants in rela-
tion to number of inhabitants in Switzerland) were within
the average of transplant rates in western Europe [12], but
for allogeneic HCT, rates were lower than in, for exam-
ple, Germany. These differences were possibly due to the
particular situation in Switzerland, which puts allogeneic
HCT under the regulation of the IVHSM (Interkantonale
Vereinbarung über die hochspezialisierte Medizin). The
data on outcome reflected the current situation. Outcome
varies according to indication and clinical situation. It is
dependent on disease, disease stage, donor type histocom-
patibility between donor and recipient in allogeneic HCT,
and on main pretransplant risk factors, as previously de-
scribed by the international transplant registries [15].
Figure 1: Main outcomes of 2781 patients with allogeneic haematopoietic cell transplants by year group in Switzerland between 1997 and
2016: (a) overall survival, (b) progression-free survival, (c) nonrelapse mortality and (d) relapse.
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The age of treated patients continues to increase and large
series of patients in their 70s receiving transplants from an
allogeneic donor have been described [16]. As age contin-
ues to increase for both allogeneic and autologous HCT,
proper evaluation of comorbidities [17] and geriatric as-
sessment become ever more important [18]. The increasing
age of treated patients is a reflection of improved technol-
ogy that allows older patients to be treated; however, these
improvements are difficult to pinpoint as they range from
the use of cytotoxic drugs for conditioning, better choice of
donor, including better tissue typing of unrelated donors,
better technology to deal with mismatched donors and bet-
ter graft-versus-host disease prophylaxis to improved man-
agement of infectious complications, transfusion support
and other aspects of supportive care [19].
Advances in therapeutic drug development have led to a
significant shift in the timing of allogeneic transplantation
in some disease categories. In chronic myeloid leukaemia,
recently most patients were transplanted after failed treat-
ment with several kinase inhibitors [20], which was re-
flected in an increase in the interval from diagnosis to HCT
from a median of 298 to 610 days. Similarly, in plasma cell
myeloma, an important number of new drugs have become
available and, as allogeneic HCT is used mainly as a sal-
vage regimen, the interval from diagnosis to HCT in these
patients increased from 538 to 823 days [21]. Therefore
outcomes in some of the disease categories have become
worse over time. For example, for allogeneic HCT 5-year
survival has dropped from 76 to 61% in chronic myeloid
leukaemia, from 48 to 34% in plasma cell myeloma and
from 53 to 42% in Hodgkin’s lymphoma. It is important to
note that since these are not entirely comparable patients
this drop in 5-year survival probabilities does not reflect
poorer technology.
As our registry does not have precise data on pretransplant
treatment, we used interval from diagnosis to treatment as
an indicator of prior therapy. It has been shown in many
studies that intensive pretreatment decreases the success
rate of allogeneic HCT. It has also been shown many times
that the number of prior treatment lines and the interval
from diagnosis to transplantation adversely impact nonre-
lapse mortality and relapse rates [15]. At the same time,
we did not have information on patients who did not need
an allogeneic HCT because of successful drug treatment.
Therefore, comparison of outcome over time has to be in-
terpreted cautiously and in the context of the global treat-
ment landscape for specific diseases.
Limitations of these data are obviously the retrospective
and observational nature of data collection and the fact that
there is no information on outcomes of alternative treat-
ments. It is among the strengths of this study that there
is complete coverage of all transplanted patients over two
decades, which is unique in Switzerland.
Table 2b: Univariate analysis of overall and progression-free survival for autologous haematopoietic cell transplants by decade for the years 1997–2016.
1997–2006 2007–2016
Overall survival at
5 years
p-value Progression-free
survival at 5
years
p-value Overall survival at
5 years
p-values Progression-free
survival at 5
years
p-values
Patients receiving first autograft (n) 2042 2042 3076 3076
59% (57–61%) 39% (37–41%) 61% (59–63%) 35% (33–37%)
Disease <0.0001 <0.0001 <0.0001 <0.0001
Acute myeloid leukaemia 44% (36–52%) 39% (31–47%) 51% (42–60%) 43% (35–51%)
Acute lymphoid leukaemia 55% (41–69%) 44% (30–58%) 39% (12–66%) 44% (18–70%)
Chronic lymphocytic leukaemia 82% (64–100%) 56% (33–79%) 33% (0–87%) 33% (0–87%)
Chronic myeloid leukaemia 25% (0–50%) 25% (0–50%) – –
Combined myelodysplastic/myeloprolifer-
ative
33% (9–57%) 29% (5–53%) 40% (0–100%) 40% (0–100%)
Hodgkin’s lymphoma 77% (70–84%) 62% (55–69%) 82% (75–89%) 63% (54–72%)
Non-Hodgkin’s lymphoma 62% (66–58%) 49% (45–53%) 61% (57–65%) 45% (41–49%)
Plasma cell disorder 60% (56–64%) 23% (20–26%) 63% (59–67%) 22% (19–25%)
Solid tumours 50% (44–56%) 41% (36–46%) 46% (38–54%) 41% (34–48%)
Autoimmune disorders 78% (50–100%) 44% (11–77%) 80% (59–100%) 71% (47–95%)
Disease stage at transplant 0.001 <0.0001 <0.0001 <0.0001
Early 60% (57–63%) 32% (29–35%) 64% (60–68%) 33% (29–37%)
Intermediate 62% (57–67%) 50% (45–55%) 64% (60–68%) 37% (33–41%)
Late 55% (51–59%) 39% (35–43%) 49% (44–53%) 36% (31–41%)
Age group <0.0001 <0.0001 <0.0001 <0.0001
0–20 years 58% (50–66%) 45% (37–53%) 51% (41–61%) 44% (35–53%)
20–40 years 64% (59–69%) 55% (50–60%) 71% (65–77%) 57% (51–63%)
40–60 years 60% (57–63%) 36% (33–39%) 64% (61–67%) 33% (30–36%)
60–7 years0 51% (46–56%) 27% (22–32%) 56% (51–61%) 30% (26–34%)
>70 years 33% (7–59%) 26% (1–51%) 40% (17–63%) 27% (10–44%)
Stem cell source 0.31 0.4 0.01 0.48
Bone marrow 50% (23–77%) 36% (10–62%) 33% (0–69%) 33% (0–69%)
Peripheral blood 59% (57–61%) 39% (37–41%) 61% (59–63%) 35% (33–37%)
Risk score 0.001 0.002 <0.0001 <0.0001
0–1 67% (57–77%) 57% (67–67%) 75% (65–85%) 62% (50–74%)
2–3 58% (54–62%) 36% (33–39%) 62% (59–65%) 34% (31–37%)
4–5 58% (56–62%) 40% (36–44%) 55% (50–60%) 35% (30–40%)
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The current analysis looked at the results of evaluation of
a registry and benefited from its 20 years of existence. It
is comforting to see that progress continues, but this oc-
curs in small steps and not in quantum leaps. Federal regu-
lations in Switzerland have made it mandatory to maintain
an evaluation registry, leading to a valuable database in-
cluding all HCTs performed in Switzerland during the peri-
od of observation, which therefore constitutes a true obser-
vational registry with complete observation of all treated
cases that will be useful for quality assurance programmes,
healthcare cost estimation and healthcare planning. Be-
tween 50 and 60% of patients are expected to survive in the
long-term after autologous and allogeneic HCT, indicating
growing populations of surviving patients requiring long-
term care and observation.
Figure 2: Main outcome of 5118 patients with autologous haematopoietic cell transplants by year group in Switzerland between 1997 and
2016: (a) overall survival, (b) progression-free survival, (c) nonrelapse mortality and (d) relapse.
Figure 3: Main outcome by risk score of 2781 patients with allogeneic haematopoietic cell transplants by decade: (a) first decade 1997–2006,
(b) second decade 2007–2016.
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CI)
p-value Progression-free
survival
Relative risk (95%
CI)
p-value Nonrelapse mor-
tality
Relative risk (95%
CI)
p-value Relapse
Relative risk (95%
CI)
p-value
Decade of Transplant 0.18 0.26
1997–2006 1 1 1 1
2007–2016 0.91 (0.80–1.05) 0.93 (0.82–1.06) 0.67 (0.52–0.86) 0.002 1.05 (0.90–1.22) 0.54
Disease <0.0001 <0.0001
Acute myeloid leukaemia 1 1 1 1
Acute lymphoid leukaemia 0.88 (0.73–1.10) 1.12 (0.94–1.35) 1.09 (0.75–1.56) 0.66 1.09 (0.88–1.34) 0.44
Chronic lymphocytic leukaemia 0.50 (0.35–0.73) 0.65 (0.47–0.89) 1.29 (0.75–2.23) 0.35 0.63 (0.44–0.90) 0.01
Chronic myeloid leukaemia 0.47 (0.35–0.62) 0.85 (0.67–1.07) 0.87 (0.53–1.47) 0.62 0.92 (0.70–1.20) 0.54
Combined myelodysplastic/myeloprolif-
erative
0.74 (0.61–0.90) 0.82 (0.68–0.99) 1.24 (0.85–1.79) 0.27 0.75 (0.59–0.95) 0.02
Myeloproliferative neoplasm 0.42 (0.30–0.59) 0.50 (0.37–0.67) 1.28 (0.77–2.11) 0.34 0.39 (0.26–0.59) <0.0001
Hodgkin’s lymphoma 0.58 (0.38–0.87) 0.75 (0.52–1.08) 2.18 (1.09–4.37) 0.03 0.51 (0.33–0.80) 0.004
Non-Hodgkin’s lymphoma 0.58 (0.45–0.76) 0.66 (0.51–0.84) 1.93 (1.30–2.85) 0.001 0.43 (0.31–0.60) 0.0001
Plasma cell disorder 1.06 (0.85–1.33) 1.34 (1.08–1.65) 1.22 (0.74–2.01) 0.44 1.33 (1.05–1.68) 0.02
Solid tumours 1.23 (0.63–2.42) 1.76 (0.89–3.45) – 2.31 (1.26–4.24) 0.01
Bone marrow failure 0.92 (0.62–1.38) 0.69 (0.45–1.04) 3.12 (1.77–5.49) <0.0001 0.13 (0.05–0.37) <0.0001
Inherited disorders of metabolism 0.61 (0.19–1.96) 1.31 (0.57–3.04) 3.16 (1.00–9.98) 0.05 0.67 (0.21–2.15) 0.50
Primary immune disorders 0.84 (0.45–1.56) 0.85 (0.47–1.51) 1.98 (0.79–4.95) 0.14 0.23 (0.93–0.58) 0.002
Haemoglobinopathy 0.19 (0.03–1.39) 0.32 (0.08–1.31) – 0.15 (0.06–1.10) 0.06
Histiocytic disorders 0.83 (0.26–2.61) 0.69 (0.22–2.17) 1.07 (0.26 –4.36) 0.92 – –
Other – – – – –
Disease stage at transplant <0.0001 <0.0001
Early 1 1 1 1
Intermediate 1.76 (1.51–2.04) 1.69 (1.47–1.95) 1.39 (1.05–1.85) 0.021 1.57 (1.28–1.79) <0.0001
Late 2.80 (2.40–3.27) 2.58 (2.22–3.0) 1.30 (0.97–1.77) 0.083 2.69 (2.25–3.23) <0.0001
Age group 0.001 0.02
0–20 years 1 1 1 1
20–40 years 1.04 (0.82–1.33) 1.23 (0.97–1.57) 0.90 (0.58–1.39) 0.64 1.51 (1.16–1.96) 0.002
40–60 years 1.39 (1.10–1.75) 1.46 (1.14–1.86) 1.54 (1.01–2.37) 0.05 1.35 (1.04–1.75) 0.02
60–70 years 1.49 (1.14–1.95) 1.49 (1.12–1.98) 1.88 (1.14–3.09) 0.01 1.26 (0.92–1.73) 0.16
>70 years 1.79 (0.92–3.48) 1.67 (0.87–3.20) 2.86 (1.13–7.25) 0.03 1.40 (0.60–3.30) 0.44
Donor <0.0001 <0.0001
HLA identical sibling 1 1 1 1
Twin 0.64 (0.35–1.17) 0.89 (0.49–1.64) 0.41 (0.05–3.18) 0.39 1.16 (0.58–2.32) 0.68
Other relative 2.01 (1.61–2.50) 1.76 (1.42–2.19) 3.27 (2.20–4.86) <0.0001 1.11 (0.84–1.45) 0.468
Unrelated 1.52 (1.33–1.74) 1.24 (0.9–1.40) 2.65 (2.04–3.45) <0.0001 0.79 (0.68–0.92) 0.002
Source 0.003
Bone marrow – 1 – –
Peripheral blood – 0.98 (0.83–1.16) – –
Cord blood – 1.84 (1.27–2.66) – –
Cytomegalovirus status (donor-recipient)
Neg-neg – – 1
Pos-neg – – 0.82 (0.55–1.23) 0.35 –
Pos-pos – – 1.05 (0.80–1.37) 0.74 –
Neg-pos – – 1.36 (1.03–1.78) 0.03 –
Conditioning 0.011
Non-myeloablative – 1 1 1
Myeloablative – 0.83 (0.72–0.96) 1.50 (1.17–1.93) 0.001 0.66 (0.55–0.78) <0.0001
T–cell depletion (in vivo or in-vitro) 0.02
No 1 – 1 –
Yes 0.85 (0.74–0.98) – 0.75 (0.59–0.95) 0.02 –
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